Correction to "Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease".

Abstract:

:[This corrects the article DOI: 10.1021/acsmedchemlett.9b00612.].

journal_name

ACS Med Chem Lett

authors

Kaiser TM,Dentmon ZW,Dalloul CE,Sharma SK,Liotta DC

doi

10.1021/acsmedchemlett.0c00336

subject

Has Abstract

pub_date

2020-06-24 00:00:00

pages

1491

issue

7

issn

1948-5875

journal_volume

11

pub_type

已发布勘误
  • Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

    abstract::Abdominal pain and abnormal bowel habits represent major symptoms for irritable bowel syndrome (IBS) patients that are not adequately managed. Although the etiology of IBS is not completely understood, many of the functions of the gastrointestinal (GI) tract are regulated by the enteric nervous system (ENS). Inflammat...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00035

    authors: Schenck Eidam H,Russell J,Raha K,DeMartino M,Qin D,Guan HA,Zhang Z,Zhen G,Yu H,Wu C,Pan Y,Joberty G,Zinn N,Laquerre S,Robinson S,White A,Giddings A,Mohammadi E,Greenwood-Van Meerveld B,Oliff A,Kumar S,Cheung M

    更新日期:2018-05-24 00:00:00

  • A new challenging and promising era of tyrosine kinase inhibitors.

    abstract::Protein kinases are key regulators that govern complex cellular processes. Dysregulation of kinase signaling is associated in many human diseases, particularly cancers and developmental and metabolic disorders. Tyrosine kinase inhibitors have achieved great success in molecular targeted therapies for cancer and now is...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500091p

    authors: Cui JJ

    更新日期:2014-03-06 00:00:00

  • Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

    abstract::A new series of potent TG2 inhibitors are reported that employ a 4-aminopiperidine core bearing an acrylamide warhead. We establish the structure-activity relationship of this new series and report on the transglutaminase selectivity and in vitro ADME properties of selected compounds. We demonstrate that the compounds...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml3001352

    authors: Prime ME,Brookfield FA,Courtney SM,Gaines S,Marston RW,Ichihara O,Li M,Vaidya D,Williams H,Pedret-Dunn A,Reed L,Schaertl S,Toledo-Sherman L,Beconi M,Macdonald D,Muñoz-Sanjuan I,Dominguez C,Wityak J

    更新日期:2012-08-09 00:00:00

  • Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

    abstract::Recently, the binding kinetics of a ligand-target interaction, such as the residence time of a small molecule on its protein target, are seen as increasingly important for drug efficacy. Here, we investigate these concepts to explain binding and proton blockage of rimantadine variants bearing progressively larger alky...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00458

    authors: Drakopoulos A,Tzitzoglaki C,McGuire K,Hoffmann A,Konstantinidi A,Kolokouris D,Ma C,Freudenberger K,Hutterer J,Gauglitz G,Wang J,Schmidtke M,Busath DD,Kolocouris A

    更新日期:2018-01-29 00:00:00

  • Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

    abstract::We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in v...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml200199c

    authors: Xue CB,Wang A,Han Q,Zhang Y,Cao G,Feng H,Huang T,Zheng C,Xia M,Zhang K,Kong L,Glenn J,Anand R,Meloni D,Robinson DJ,Shao L,Storace L,Li M,Hughes RO,Devraj R,Morton PA,Rogier DJ,Covington M,Scherle P,Diamond

    更新日期:2011-10-05 00:00:00

  • Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.

    abstract::A new class of 4-aminoquinolines was synthesized and evaluated in vitro for antiplasmodial activity against both the chloroquine-sensitive (3D7) and -resistant (K1 and W2) strains. The most active compounds 3c-3e had acceptable cytotoxicity but showed strong inhibition toward a panel of cytochrome P450 enzymes in vitr...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400311r

    authors: Tukulula M,Njoroge M,Abay ET,Mugumbate GC,Wiesner L,Taylor D,Gibhard L,Norman J,Swart KJ,Gut J,Rosenthal PJ,Barteau S,Streckfuss J,Kameni-Tcheudji J,Chibale K

    更新日期:2013-10-01 00:00:00

  • Structure-based ligand design of novel bacterial RNA polymerase inhibitors.

    abstract::Bacterial RNA polymerase (RNAP) is essential for transcription and is an antibacterial target for small molecule inhibitors. The binding region of myxopyronin B (MyxB), a bacterial RNAP inhibitor, offers the possibility of new inhibitor design. The molecular design program SPROUT has been used in conjunction with the ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml200087m

    authors: McPhillie MJ,Trowbridge R,Mariner KR,O'Neill AJ,Johnson AP,Chopra I,Fishwick CW

    更新日期:2011-07-29 00:00:00

  • Novel Type of Prodrug Activation through a Long-Range O,N-Acyl Transfer: A Case of Water-Soluble CREB Inhibitor.

    abstract::CREB (cAMP response element binding protein) has been shown to play an important role in tumor initiation, progression, and metastasis. We discovered that naphthol AS-E, a cell-permeable CREB inhibitor, presented antiproliferative activity in a broad panel of cancer cell lines in vitro. However, it has limited aqueous...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500330n

    authors: Li BX,Xie F,Fan Q,Barnhart KM,Moore CE,Rheingold AL,Xiao X

    更新日期:2014-08-22 00:00:00

  • Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

    abstract::Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00119

    authors: Hoegenauer K,Soldermann N,Stauffer F,Furet P,Graveleau N,Smith AB,Hebach C,Hollingworth GJ,Lewis I,Gutmann S,Rummel G,Knapp M,Wolf RM,Blanz J,Feifel R,Burkhart C,Zécri F

    更新日期:2016-06-02 00:00:00

  • Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.

    abstract::The atypical chemokine receptor CXCR7 has been studied in various disease settings including immunological diseases and heart disease. Efforts to elucidate the role of CXCR7 have been limited by the lack of suitable chemical tools with a range of pharmacological profiles. A high-throughput screen was conducted to disc...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00163

    authors: Menhaji-Klotz E,Ward J,Brown JA,Loria PM,Tan C,Hesp KD,Riccardi KA,Litchfield J,Boehm M

    更新日期:2020-05-14 00:00:00

  • Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.

    abstract::Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs. ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00181

    authors: Oehlrich D,Peschiulli A,Tresadern G,Van Gool M,Vega JA,De Lucas AI,Alonso de Diego SA,Prokopcova H,Austin N,Van Brandt S,Surkyn M,De Cleyn M,Vos A,Rombouts FJR,Macdonald G,Moechars D,Gijsen HJM,Trabanco AA

    更新日期:2019-07-02 00:00:00

  • Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites.

    abstract::Neuromedin U (NMU) and S (NMS) display various physiological activities, including an anorexigenic effect, and share a common C-terminal heptapeptide-amide sequence that is necessary to activate two NMU receptors (NMUR1 and NMUR2). On the basis of this knowledge, we recently developed hexapeptide agonists 2 and 3, whi...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500494j

    authors: Takayama K,Mori K,Sohma Y,Taketa K,Taguchi A,Yakushiji F,Minamino N,Miyazato M,Kangawa K,Hayashi Y

    更新日期:2015-01-28 00:00:00

  • Synthesis and Cardiac Imaging of (18)F-Ligands Selective for β1-Adrenoreceptors.

    abstract::A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood poo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml1002458

    authors: Radeke HS,Purohit A,Harris TD,Hanson K,Jones R,Hu C,Yalamanchili P,Hayes M,Yu M,Guaraldi M,Kagan M,Azure M,Cdebaca M,Robinson S,Casebier D

    更新日期:2011-07-22 00:00:00

  • Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides.

    abstract::The acyldepsipeptide (ADEP) antibiotics operate through a clinically unexploited mechanism of action and thus have attracted attention from several antibacterial development groups. The ADEP scaffold is synthetically tractable, and deep-seated modifications have produced extremely potent antibacterial leads against Gr...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00320

    authors: Li Y,Lavey NP,Coker JA,Knobbe JE,Truong DC,Yu H,Lin YS,Nimmo SL,Duerfeldt AS

    更新日期:2017-10-19 00:00:00

  • Discovery of a Series of Indazole TRPA1 Antagonists.

    abstract::A series of TRPA1 antagonists is described which has as its core structure an indazole moiety. The physical properties and in vitro DMPK profiles are discussed. Good in vivo exposure was obtained with several analogs, allowing efficacy to be assessed in rodent models of inflammatory pain. Two compounds showed signific...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00140

    authors: Pryde DC,Marron BE,West CW,Reister S,Amato G,Yoger K,Antonio B,Padilla K,Cox PJ,Turner J,Warmus JS,Swain NA,Omoto K,Mahoney JH,Gerlach AC

    更新日期:2017-05-18 00:00:00

  • Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.

    abstract::We have developed a novel albumin-binding prodrug of doxorubicin that incorporates p-aminobenzyloxycarbonyl (PABC) as a 1,6 self-immolative spacer in addition to the heptapeptide, Arg-Ser-Ser-Tyr-Tyr-Ser-Leu, as a substrate for the prostate-specific antigen (PSA) that is overexpressed in prostate carcinoma and represe...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml100060m

    authors: Elsadek B,Graeser R,Warnecke A,Unger C,Saleem T,El-Melegy N,Madkor H,Kratz F

    更新日期:2010-05-26 00:00:00

  • Discovery of 1,4-Naphthoquinones as a New Class of Antiproliferative Agents Targeting GPR55.

    abstract::A new series of 1,4-naphthoquinones, bearing various cyclic and aliphatic amines on C2, was designed and synthesized to identify antiproliferative agents for triple-negative breast cancer, which represents a clinical challenge without targeted therapies. Among naphthoquinones, 2a and 3a inhibited the proliferation of ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00333

    authors: Badolato M,Carullo G,Caroleo MC,Cione E,Aiello F,Manetti F

    更新日期:2019-02-15 00:00:00

  • Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.

    abstract::Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-XL inhibitor A-1155463 using structure-based drug design. Key design ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00568

    authors: Wang L,Doherty GA,Judd AS,Tao ZF,Hansen TM,Frey RR,Song X,Bruncko M,Kunzer AR,Wang X,Wendt MD,Flygare JA,Catron ND,Judge RA,Park CH,Shekhar S,Phillips DC,Nimmer P,Smith ML,Tahir SK,Xiao Y,Xue J,Zhang H,Le PN

    更新日期:2020-03-30 00:00:00

  • Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.

    abstract::Cellular proteins that fail to fold properly result in inactive or disfunctional proteins that can have toxic functions. The unfolded protein response (UPR) is a two-tiered cellular mechanism initiated by eukaryotic cells that have accumulated misfolded proteins within the endoplasmic reticulum (ER). An adaptive pathw...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5003234

    authors: Flaherty DP,Miller JR,Garshott DM,Hedrick M,Gosalia P,Li Y,Milewski M,Sugarman E,Vasile S,Salaniwal S,Su Y,Smith LH,Chung TD,Pinkerton AB,Aubé J,Callaghan MU,Golden JE,Fribley AM,Kaufman RJ

    更新日期:2014-10-29 00:00:00

  • Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.

    abstract::A novel series of alkoxyimino derivatives as S1P1 agonists were discovered through de novo design using FTY720 as the chemical starting point. Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carbo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300396r

    authors: Pan S,Gray NS,Gao W,Mi Y,Fan Y,Wang X,Tuntland T,Che J,Lefebvre S,Chen Y,Chu A,Hinterding K,Gardin A,End P,Heining P,Bruns C,Cooke NG,Nuesslein-Hildesheim B

    更新日期:2013-01-04 00:00:00

  • Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.

    abstract::The renal outer medullary potassium channel (ROMK or Kir1.1) is a putative drug target for a novel class of diuretics that could be used for the treatment of hypertension and edematous states such as heart failure. An internal high-throughput screening campaign identified 1,4-bis(4-nitrophenethyl)piperazine (5) as a p...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml3000066

    authors: Tang H,Walsh SP,Yan Y,de Jesus RK,Shahripour A,Teumelsan N,Zhu Y,Ha S,Owens KA,Thomas-Fowlkes BS,Felix JP,Liu J,Kohler M,Priest BT,Bailey T,Brochu R,Alonso-Galicia M,Kaczorowski GJ,Roy S,Yang L,Mills SG,Garcia M

    更新日期:2012-03-28 00:00:00

  • Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

    abstract::The selectivity of histone deacetylase inhibitors (HDACis) is greatly impacted by the zinc binding groups. In an effort to search for novel zinc binding groups, we applied a parallel medicinal chemistry (PMC) strategy to quickly synthesize substituted benzamide libraries. We discovered a series containing 2-substitute...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00462

    authors: Liu J,Yu Y,Kelly J,Sha D,Alhassan AB,Yu W,Maletic MM,Duffy JL,Klein DJ,Holloway MK,Carroll S,Howell BJ,Barnard RJO,Wolkenberg S,Kozlowski JA

    更新日期:2020-10-13 00:00:00

  • Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment.

    abstract::Membrane-bound pyrophosphatases (mPPases) regulate energy homeostasis in pathogenic protozoan parasites and lack human homologues, which makes them promising targets in e.g. malaria. Yet only few nonphosphorus inhibitors have been reported so far. Here, we explore an isoxazole fragment hit, leading to the discovery of...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00537

    authors: Johansson NG,Turku A,Vidilaseris K,Dreano L,Khattab A,Ayuso Pérez D,Wilkinson A,Zhang Y,Tamminen M,Grazhdankin E,Kiriazis A,Fishwick CWG,Meri S,Yli-Kauhaluoma J,Goldman A,Boije Af Gennäs G,Xhaard H

    更新日期:2020-02-17 00:00:00

  • Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.

    abstract::Synthesis of a strict structural analogue of albaconazole in which the quinazolinone ring is fused by a thiazole moiety led to the discovery of a new triazole with broad-spectrum antifungal activity. Compound I exhibited high in vitro activity against pathogenic Candida species and filamentous fungi and showed prelimi...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300429p

    authors: Guillon R,Pagniez F,Picot C,Hédou D,Tonnerre A,Chosson E,Duflos M,Besson T,Logé C,Le Pape P

    更新日期:2013-01-17 00:00:00

  • Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

    abstract::Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alt...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00421

    authors: Popovici-Muller J,Lemieux RM,Artin E,Saunders JO,Salituro FG,Travins J,Cianchetta G,Cai Z,Zhou D,Cui D,Chen P,Straley K,Tobin E,Wang F,David MD,Penard-Lacronique V,Quivoron C,Saada V,de Botton S,Gross S,Dang L,Y

    更新日期:2018-01-19 00:00:00

  • Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.

    abstract::A series of bis(l-amino acid) ester prodrugs of tenofovir (TFV) were designed and synthesized as new anti-HBV agents in this work. Four compounds 11, 12a, 12d, and 13b displayed better anti-HBV activity (IC50: 0.71-4.22 μM) than the parent drug TFV. The most active compound 11 (IC50: 0.71 μM), a bis(l-valine) ester pr...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00184

    authors: Wang A,Wu S,Tao Z,Li X,Lv K,Ma C,Li Y,Li L,Liu M

    更新日期:2019-05-16 00:00:00

  • Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression.

    abstract::The multistep preparation of (11)C-levetiracetam ((11)C-LEV) was carried out by a one-pot radiosynthesis with 8.3 ± 1.6% (n = 8) radiochemical yield in 50 ± 5.0 min. Briefly, the propionaldehyde was converted to propan-1-imine in situ as labeling precursor by incubation with ammonia. Without further separation, the im...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500285t

    authors: Cai H,Mangner TJ,Muzik O,Wang MW,Chugani DC,Chugani HT

    更新日期:2014-08-19 00:00:00

  • Salinomycin Hydroxamic Acids: Synthesis, Structure, and Biological Activity of Polyether Ionophore Hybrids.

    abstract::The polyether ionophore salinomycin has recently gained attention due to its exceptional ability to selectively reduce the proportion of cancer stem cells within a number of cancer cell lines. Efficient single step strategies for the preparation of hydroxamic acid hybrids of this compound varying in N- and O-alkylatio...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00079

    authors: Borgström B,Huang X,Chygorin E,Oredsson S,Strand D

    更新日期:2016-04-25 00:00:00

  • 1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant Acinetobacter baumannii.

    abstract::With only two new classes of antibiotics developed in the last 40 years, novel antibiotics are desperately needed to combat the growing problem of multidrug-resistant and extensively drug resistant bacteria, particularly Gram-negative bacteria. Described in this letter is the synthesis and antibiotic activity of 1,2,4...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00296

    authors: Huggins WM,Minrovic BM,Corey BW,Jacobs AC,Melander RJ,Sommer RD,Zurawski DV,Melander C

    更新日期:2016-11-12 00:00:00

  • In Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated Dmt1-DALDA Analogues.

    abstract::In this study the μ opioid receptor (MOR) ligands DALDA (Tyr-d-Arg-Phe-Lys-NH2) and Dmt1-DALDA (Dmt-d-Arg-Phe-Lys-NH2, Dmt = 2',6'-dimethyltyrosine) were glycosylated at the N- or C-terminus. Subsequently, the modified peptides were subjected to in vitro and in vivo evaluation. In contrast to the N-terminally modified...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml4004765

    authors: Ballet S,Betti C,Novoa A,Tömböly C,Nielsen CU,Helms HC,Lesniak A,Kleczkowska P,Chung NN,Lipkowski AW,Brodin B,Tourwé D,Schiller PW

    更新日期:2014-04-10 00:00:00